Spero Therapeutics, Inc.
Moat Score — Spero Therapeutics, Inc.
Total Moat Score
10 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Utebzi (tebipenem pivoxil) carries composition-of-matter and formulation patents plus QIDP-related exclusivity extensions layered on standard NCE exclusivity, and is now a real FDA-approved asset (approved June 2026) rather than a paper candidate. The July 2026 SP001 in-license adds Innovent's antibody IP, but Spero owns no broad platform technology -- its portfolio is a small set of licensed-in/licensed-out single assets. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Spero has no proprietary manufacturing scale or distribution cost edge; it is a licensing/R&D organization that depends entirely on GSK (and Meiji) to manufacture and sell Utebzi, and would depend on Innovent/Fortvita-linked supply for SP001. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Utebzi's novelty as the only oral carbapenem for resistant complicated UTIs could support premium hospital/outpatient pricing, but GSK -- not Spero -- sets and captures list price; Spero's economics are a tiered royalty once removed from any pricing decision. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Spero's out-license/in-license biopharma model has no two-sided market, platform, or user network dynamic of any kind. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once hospitalists and urologists adopt Utebzi as an oral step-down for drug-resistant cUTI and it enters hospital formularies, prescriber and formulary inertia creates some stickiness for the drug itself, which indirectly protects Spero's royalty stream. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Complicated UTI caused by resistant Gram-negative pathogens and IgG4-related disease are each sizeable-but-niche markets where regulatory exclusivity (QIDP, orphan-type dynamics) can discourage new entrants, though this scale protection accrues mainly to commercial partners GSK and, eventually, to Spero's royalty share rather than to Spero's own operations. |